= Emerging. More than 5 years before clinical availability. (9.82%)
= Expected to be clinically available in 1 to 4 years. (12.95%)
= Clinically available now. (22.77%)
MSACL 2018 EU : Rappold

MSACL 2018 EU Abstract

Topic: Practical Training

Podium Presentation in the Ether on Thursday at 15:10 (Chair: Brian Rappold)

3/3 Getting Lower Limits of Quantification in LC-MS/MS assays : The Words Don’t Fit the Picture

Brian Rappold (Presenter)

Presenter Bio(s): Brian Rappold is the Director of Mass Spectrometry for LabCorp. He's participated in MSACL EU since its inception, leading workshops and teaching short courses related to method development and validation strategies.

Authors: Brian Rappold
Laboratory Corporation of America


In the concluding lecture of the series, data from experiments previously described will be shown, including the results of precision-improving transition summing and solvent screening. The rationales behind analyte losses in handling and analysis will be discussed, as well as the limitations to the approaches examined. Understanding why titles of albums by Willie Nelson were selected for lecture titles shall also be briefly investigated.

Financial Disclosure

Board MemberyesMetabolomic Diagnostics
Stockyes LabCorp
IP Royaltyno

Planning to mention or discuss specific products or technology of the company(ies) listed above: